NCT03878784

PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea

Investigation of PACAP38-induced Headache and Rosacea-like Symptoms in Patients With Rosacea

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Danish Headache Center · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The investigators aim is to investigate the incidence of headache and rosacea-like flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with rosacea

Detailed description

Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in rosacea pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in migraine patients. PACAP38 also induces flushing which may imitate rosacea-like flushing. We are investigating whether the flushing after PACAP38 resembles rosacea-like flushing, and whether treatment with sumatriptan has an effect on the headache and flushing effects of PACAP38. The purpose of this study is to investigate PACAP38-induced headache and flushing in patients with rosacea who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The investigators will use a double-blind, placebo-controlled crossover study design to investigate this.

Conditions

• Rosacea

Interventions

Type	Name	Description
DRUG	Imigran	All patients will undergo this intervention on one of two study days
OTHER	Isotonic Saline	All patients will undergo this intervention on one of two study days

Timeline

• Start date: 2018-11-12
• Primary completion: 2019-12-19
• Completion: 2019-12-19
• First posted: 2019-03-18
• Last updated: 2020-03-26

Locations

1 site across 1 country: Denmark